1990 Volume 52 Issue 2 Pages 365-370
The clinical efficacy and safety of 3% vidarabine ointment (MJD-1741) were evaluated in 38 patients with herpes simplex virus infections. The 38 patients comprised of 31 herpes labialis, 2 Kaposi’s varicelliform eruption, one herpes genitalis, two herpes facial infections, and one each of the buttocks and the hand and lips. The effectiveness rate, which means the percentage of patients with a “moderate improvement” or better response, in patients with herpes simplex was 50.0%. And the percentage of patients with “slight improvement” or better response was 81.6%. The treatment of MJD-1741 was shown to cause neither side effects nor any abnormal laboratory findings.
